Podcasts about science daily

Today on Tech and Science Daily from The Standard: the latest on the Westminster and Kensington & Chelsea cyber incident, a quantum year-end update from Imperial and the London Quantum Cluster, and UKRI's shift toward growth funding — including video games. Plus, Revolut's new UK mobile service, Alexa+ arriving on the web, and a couple of practical gaming and headset updates Hosted on Acast. See acast.com/privacy for more information.

Real Life We kick things off with Real Life, where Devon is suspiciously chipper and ahead on billing (don't worry, it doesn't last forever). Steven recounts The Great Lice Infestation of '25, a saga that will echo through the ages—or at least the household laundry room. Ben crowns Sektori as his game of the year, describing it as the best Dreamcast game that never existed and somehow got a remaster. If that sentence alone sells you, here's the deal-tracking rabbit hole via IsThereAnyDeal . Bennnip. Steven also recommends Arc Raiders, a loot-em-up that caught his attention, which leads to a discussion of an AI-related controversy surrounding the game. Ben had heard about it, and we dig into what's actually going on, pulling from this breakdown over at Game Rant: Arc Raiders Gen AI Voice Acting Controversy Explained Back at the table, Steven ran a Mutant Crawl Classics game where a gravitational-lensing mutant plant man absolutely stole the show. As they do. Future or Now Ben brings science to the table with a discussion on tea, coffee, and bone health. He walks us through a decade-long study of older women that found tea drinkers had slightly stronger bones, while moderate coffee consumption caused no harm. Heavy coffee intake—more than five cups a day—was associated with lower bone density, especially when paired with higher alcohol consumption. Tea's benefits may come from catechins that help support bone formation, and the researchers suggest that small daily habits can add up over time. Ben even ran the ScienceDaily article through Google LM to compare it against the original paper. You can read the summary here: Tea may strengthen bones in older women while heavy coffee weakens them Devon tackles a much bigger question: why consciousness exists at all. The research suggests consciousness evolved in layers—starting with basic survival responses like pain and alarm, then expanding into focused awareness and self-reflection. These layers help organisms learn, avoid danger, and coordinate socially. Birds, interestingly, display many of these traits, implying that consciousness may be far older and more widespread than we once thought. The full write-up is worth your time: Why consciousness exists at all Steven had nothing this week, which is honestly its own kind of achievement. Book Club This week's discussion centers on "The Red Thread" by Sofia Samatar, published in Lightspeed Magazine. The story features strong prose, an evocative world, and a compelling narrative voice. Devon respected it but didn't fully connect, while Ben loved it and Steven greatly enjoyed the ride. You can read it here: "The Red Thread" by Sofia Samatar Looking ahead, next week's pick is "The Janitor in Space" by Amber Sparks, which you can find at American Short Fiction: The Janitor in Space — As always, thanks for listening—and remember: drink some tea, question reality, and check your kids for lice.

Ofcom investigates BT's EE and Three after major call outages affected emergency services, plus King's College London research aiming to give robots a sense of touch. We also hear from Pinterest's Sidney Stanback on the Pinterest Predicts 2026 report and how trend forecasting is speeding up, then cover the UK's quantum push with Google's Willow processor, an autonomous spacecraft rendezvous milestone, a UK-backed plan to produce lead-212 radiotherapy isotopes from reprocessed uranium, a warning on budget smartphone pricing pressures in 2026, and a quick gaming performance update from Capcom. For more, visit standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

In today's episode of Tech and Science Daily from The Standard, we start in London with AI visuals imagining what a six-metre sea level rise could mean for landmarks like Westminster and the Tower of London. Then we break down the Lancet Countdown 2025 findings on climate change and public health, from heat impacts to air pollution, and why it matters for cities like London. Plus, a lighter science story: researchers at Rothera Research Station in Antarctica get a brand-new Royal Mail postbox delivered via the RRS Sir David Attenborough. For more tech and science news, head to standard.co.uk Hosted on Acast. See acast.com/privacy for more information.

Welcome to Ozempic Weightloss Unlocked, the show that unpacks how these medicines are reshaping health, lifestyle, and the science of weight loss.Ozempic is the brand name for semaglutide, a glucagon like peptide one medicine originally approved for type two diabetes that also leads to significant weight reduction. Clinical trials like the STEP program, published in journals such as The New England Journal of Medicine and summarized by the journal Obesity, show average weight loss around fifteen percent of body weight over a little more than a year when combined with lifestyle changes.Real world reports collected by MedShadow describe how some people see dramatic improvements in blood sugar, blood pressure, and joint pain, while others struggle with nausea, constipation, heartburn, or even mood changes. One long term study cited by MedShadow found that people who stopped semaglutide regained about seventy percent of the weight they had lost, highlighting that this often works best as a long term treatment, not a quick fix.According to Rutgers University Camden, most studies so far run only one to two years and show ten to fifteen percent weight loss, but also high discontinuation rates due to side effects or access problems. That raises big questions about sustainability, cost, and what it means for body image to live in an era where powerful appetite changing drugs are widely used.There is also breaking science beyond injectable Ozempic. Advisory Board reports that Novo Nordisk has developed an oral semaglutide pill that produced about sixteen and a half percent weight loss over sixty four weeks, similar to the injection, and has been submitted for approval. Eli Lilly is developing another pill, orforglipron, which led to about twelve percent weight loss in trials without strict food timing rules, making it potentially easier to take.Then there isn't just double, but triple hormone targeting on the horizon. Advisory Board and ABC News describe retatrutide, sometimes called the triple G drug, which mimics three gut hormones. In early trials, people on the highest dose lost around twenty four to almost twenty nine percent of their body weight in about a year to sixteen months, and those with knee arthritis also reported large reductions in pain. These drugs are not yet approved, but multiple large phase three trials are underway.At the same time, researchers in Sweden, writing in the journal Cell and reported by outlets like Fox News and Prevention, are testing a completely different approach, an oral drug sometimes called ATR two five eight that acts more like exercise in a pill. Instead of mainly reducing appetite like Ozempic, it boosts muscle metabolism, improves blood sugar, increases fat burning, and seems to preserve muscle mass, at least in early animal and phase one human studies. If future trials confirm this, it could be combined with glucagon like peptide one drugs to protect muscle while enhancing weight loss.There may even be brain benefits. Science Daily recently covered an analysis suggesting that people with type two diabetes using glucagon like peptide one medicines such as Ozempic, Trulicity, or Victoza were less likely to develop epilepsy, hinting that these drugs might have protective effects in the brain. That research is still emerging, but it adds to ongoing studies on dementia, stroke, and other neurologic conditions.So where does all of this leave you as a listener trying to make sense of the Ozempic era? The evidence shows that semaglutide and related medicines can deliver double digit percentage weight loss, improve blood sugar, and reduce some obesity related risks. But they can cause side effects, are often expensive, and may need to be taken long term to keep the weight off. New pills and next generation drugs promise more convenience, more weight loss, and possibly fewer trade offs like muscle loss, yet they also raise fresh questions about safety, access, and how these medicines will change daily life, from what and how we eat to how we think about our bodies.On future episodes of Ozempic Weightloss Unlocked, we will dive deeper into personal stories, long term safety data, mental health, and practical tips for living well on these medicines, or deciding when they are not the right fit.Thank you for tuning in, and please remember to subscribe so you never miss an update on this fast moving world of Ozempic and weight loss science.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this Friday episode of Tech and Science Daily from The Standard, we look at a new UK sound therapy that has reduced tinnitus loudness in trials and could one day be delivered by smartphones. We round up December 2025's biggest new game releases before an interview with Which? editor Harry Rose on their Top 50 products of the year – including that headline-grabbing Asda ketchup ranking. We end on a good-news climate story, as a $24.5m Bezos Earth Fund package moves the world's first cross-border marine biosphere reserve in the eastern Pacific a step closer to reality. Hosted on Acast. See acast.com/privacy for more information.

Real Life We opened this week's episode with real-life updates, starting with Steven's full-on birthday blitz — his birthday, his kids' birthdays, all packed into the same window. There was dinner out, a rowdy round of Ransom Notes, and the proud report that his kid nailed a fully successful sleepover. Parenting achievement unlocked. Devon, meanwhile, came in questioning reality: The Onion is still a newspaper? That somehow turned into a whole debate about debates (1 vs. 20 participants), which feels about right. And then his kid dropped the big question at home: how do we stop an asteroid from hitting Earth? Devon chose the only responsible answer: we "Armageddon" it. Ben ended up on a binge of Home Alone and Hawkeye, which is a surprisingly coherent double feature when you think about it. Future or Now Steven: Why '90s Brains Are Built Differently Steven brought a pair of articles that explore why '90s kids' brains diverged from Gen Z's: a piece from Psychology Zine (link) and a supporting breakdown from Newsweek (link). If you grew up racing Rainbow Road in Mario Kart or discovering secrets in Pokémon Red without a guidebook, you remember when games came in chunky cartridges, had clear endings, and handed out failure like candy. You got better, or you started over. That era hard-coded a very different reward system. Compare that to now: kids juggling Fortnite battle passes, chasing Roblox skins with real money, and fending off constant push notifications baiting FOMO. According to the experts in those articles, this shift isn't just technological — it's actually altering how developing brains handle challenge, reward, and attention. Devon: Can We Finally Trust Quantum Computers? Devon dug into a fascinating breakthrough in quantum computing. Scientists have developed a method that can validate results from quantum computers in minutes instead of millennia. The report came from ScienceDaily (link) and the deeper technical writeup appeared in Quantum Science and Technology (IOP link). Right now, quantum devices — especially GBS machines — are notoriously noisy, and verifying their answers is so computationally hard that we usually just trust whatever they spit out. This new technique already exposed errors in a major earlier experiment, which is both alarming and encouraging. If we want reliable quantum hardware, this is exactly the step we needed. Ben: Giants on the Icelandic Landscape Ben found something visually stunning: a design project that turns routine electrical pylons into towering human-shaped sculptures across Iceland. They're eerie, monumental, and beautiful in a way infrastructure never gets to be. You can see the concept on the designer's site here: choishine.com (link). These pylon-giants use only minor structural tweaks to standard tower design, but the transformation is dramatic. Instead of anonymous metal frames, the landscape gets colossal steel figures marching across the horizon. Book Club This Week: "Dark Air" by Lincoln Michel We read "Dark Air" this week — a moody, unsettling story that mixes environmental dread with strange atmospheric phenomena. You can read it for free on Granta: granta.com/dark-air Next Week: "The Red Thread" by Sofia Samatar Next up is Sofia Samatar's "The Red Thread" — intricate, mythic, and exactly the kind of story we love diving into. You can read it on Lightspeed Magazine: lightspeedmagazine.com/fiction/the-red-thread

On today's Tech and Science Daily from The Standard, we look at NHS warnings over a record “superflu” wave hitting London and what it means for hospitals and daily life in the capital. We break down the 5.8% Tube fare rise coming next March and a new AI carers' support trial in Richmond. After the break, we cover a fresh MIT study on how the brain and immune system team up to keep you in bed when you're sick, PlayStation's 2025 Wrap-Up gaming recap, and Samsung's latest Android XR upgrade for its Galaxy XR headset. For more head to standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

On today's Tech and Science Daily from The Standard, we're in London for the city's share of a major innovation fund and a Royal Society summit on marine biodiversity, fishing and climate change, with a quick nod to the UK Biobank Scientific Conference in Westminster. We're also joined by Andy Watson, co-founder and CEO of Claimit, to help us understand why lost parcels are costing businesses billions. After the interview, we chat the Geminid meteor shower over London and unpack a new study testing garlic mouthwash against standard antiseptics. For the latest news head to standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

On today's Tech and Science Daily from The Standard, we break down new TfL lift tech for step-free travel, explain a major UCL study on how air pollution can weaken the benefits of exercise, and look at Cloudflare's latest outage hitting LinkedIn and Zoom. We also cover a huge neutrino collaboration that could explain why the universe exists, December's PlayStation Plus free games and upcoming Game Awards 2025, and Amazon's new Alexa Plus scene-skipping feature for Fire TV. Hosted on Acast. See acast.com/privacy for more information.

In today's episode of Tech and Science Daily from The Standard, we look at a West London GP surgery trialling Mirror, an AI “patient scribe” that helps NHS patients remember their appointments, and the UK's world-first mobile quantum brain scanner designed to study blast effects on troops. We're also joined by Samsung UK & Ireland Chief Customer Officer Deborah Honig to discuss new research on decision fatigue and how AI could ease everyday choices. Plus, we round up December's Xbox Game Pass games, Jorja Smith's AI clone drama, and explain why Android's latest security update is a must-install for your phone. Hosted on Acast. See acast.com/privacy for more information.

In today's Tech and Science Daily from The Standard, we break down the cyber attacks hitting multiple London councils, warnings of a “historic winter crisis” in the capital's A&Es, and a major update to Ordnance Survey's underground mapping project as Openreach joins the National Underground Asset Register.We also take a look at a new UK cyber tool blocking nearly a billion malicious web attempts, hydrogen tech cutting rail maintenance emissions, and a UK-led breakthrough in quantum teleportation between linked networks. Plus, December's first PlayStation Plus game, and YouTube Recap 2025.For all the latest news, head to standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

Welcome to the O2X limited series Optimizing Parenthood - A Guide to Leading the Next Generation.Over this 5 episode limited series we will explore the science, strategies, and practical wisdom behind raising healthy, confident, and resilient young adults. Hosted by O2X Vice President of Government Brendan Stickles, this podcast brings together leading experts in sleep science, nutrition, fitness, psychology, and personal development to help parents navigate the complexities of modern parenting.Episode #3 features O2X Nutrition Specialist Nick Barringer. Nick currently researches and serves as an assistant professor at the United States Military Academy. Previously while working at the United States Army Research Institute of Environmental Medicine he researched Warfighter nutritional requirements in differing environments to include deployed Special Operators. Prior to that, he taught performance nutrition at the Army-Baylor Graduate Program in Nutrition. Nick served in the 75th Ranger Regiment as a member of the Ranger Athlete Warrior (RAW) program where he oversaw the nutrition and aspects of the physical training of Rangers. He received his undergraduate degree in dietetics from the University of Georgia, his master of science in exercise science from California University of Pennsylvania and his doctorate in kinesiology from Texas A&M. Nick is passionate about improving nutrition and performance in tactical athletes and has the unique perspective of a researcher, teacher, and practitioner who has gone through physically demanding courses such as Ranger School, Survival Evasion Resistance Escape (SERE), Airborne, Air Assault as well as having deployed to both Iraq and Afghanistan so he best understands both the academic and applied demands of the tactical athlete. Nick has presented at both national and international conferences on tactical athlete nutrition and performance and his research has appeared in multiple media outlets such as Science Daily and Men's Journal.Be sure to tune into the following episodes over the following weeks...Episode 1: Dr. Katy Turner on building confidence and resilience within young adults Episode 2: Dr. Jaime Tartar on optimizing sleep schedules for the whole family  Episode 3: Dr. Nick Barringer on developing sustainable and healthy eating habitsEpisode 4: Josh Lamont on creating fitness habits in our youthEpisode 5: Adam La Reau on introducing goal setting and habit building to young adultsBuilding Homes for Heroes:https://www.buildinghomesforheroes.org/Download the O2X Tactical Performance App:app.o2x.comLet us know what you think:Website - http://o2x.comIG - https://instagram.com/o2xhumanperformance?igshid=1kicimx55xt4f 

On today's Tech and Science Daily from The Standard, we break down the UK Government's decision to back Heathrow's third runway plans and speak to UN tourism adviser Anita Mendiratta about what the expansion means for London, the environment and rival European hubs. We also look at how power-hungry data centres are worsening the capital's housing crisis, why Hammersmith & Fulham wants drones to tackle crime, and Uber's new autonomous delivery robots launching in UK cities. Plus, we cover Samsung's Galaxy Z TriFold foldable phone and the biggest gaming releases landing this December.For all the latest news, head to standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

On today's Tech and Science Daily from The Standard, we look at Puma's massive new Oxford Street flagship store, Stansted and Southend finally joining London's contactless rail network, and how wetter winters are forcing the UK transport system to adapt. We also speak to Tim Johnson from the Civil Aviation Authority about staying safe from Travel Tuesday holiday scams, break down HSBC's new AI partnership with French startup Mistral AI, and run through December's biggest game releases – plus the best Cyber Monday tech deals for Londoners.For all the latest news, head to standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

On today's Tech and Science Daily from The Standard we explain what the digital phone switchover means for London landline and telecare users, break down how the latest UK Budget plans to keep high-growth tech firms and R&D jobs in Britain, and look at UCL's role in uncovering a vast Bronze Age “mega city”. We also dive into a newly discovered deep-sea hotspot bursting with life, Nintendo's acquisition of Bandai Namco's Singapore studio, and a cosy sci-fi life-sim shadow-dropping into Xbox Game Pass.For all the latest news, head to standard.co.uk. Hosted on Acast. See acast.com/privacy for more information.

On today's Tech and Science Daily from The Standard, we cover DLR cleaners striking over sick pay on London's driverless railway, the Courtauld's £82m plan to transform Somerset House into a state-of-the-art campus, and new UK analysis warning that over-reliance on carbon removals could push up climate costs. In gaming, Cyberpunk 2077 passes 35 million sales and outpaces The Witcher 3, while in consumer tech Apple is tipped to overtake Samsung as the world's top smartphone seller thanks to the iPhone 17. Plus, we're joined by Which? to reveal why eight in ten Black Friday “bargains” are often the same price, or cheaper, at other times of the year – and how to shop smarter this weekend. Hosted on Acast. See acast.com/privacy for more information.

Welcome to Ozempic Weightloss Unlocked, the show where we dive deep into the latest updates, science, and real-world impact of Ozempic and similar medications on health and lifestyle.Ozempic, once mainly a diabetes treatment, has quickly become one of the most talked-about weight loss options worldwide, reshaping the way people approach long-term health. According to the CREO Clinic, around 12 percent of adults in the United States have now used a GLP-1 medication like Ozempic or Wegovy. The surge is so significant that it recently brought about shortages, prompting the Food and Drug Administration to permit other companies to produce compounded semaglutide medications. However, the original manufacturer, Novo Nordisk, warns that these non-branded pills are not Food and Drug Administration approved and might bring safety concerns. They have responded by filing over one hundred lawsuits against providers of these versions.The numbers behind these medications are striking. In clinical trials, people taking semaglutide, the active ingredient in Ozempic and Wegovy, lost on average close to 15 percent of their body weight over about a year and a half. For another drug in the same class, called tirzepatide, users lost over 20 percent on average. This is a magnitude of weight loss rarely seen with previous medical approaches.The real-world experience, though, tells a slightly different story. Outside of clinical trials, users of Ozempic typically see about a 7 to 8 percent drop in their body weight after one year. For tirzepatide, the average is closer to 12 percent. Experts say that even five percent weight loss can be enough to improve many health conditions tied to weight, including blood sugar issues and high pressure in the arteries.The difference between clinical trials and real life may be due to a range of factors. About half of all patients stop taking these medications within the first year and four out of five end up on lower than the recommended doses. Clinical trials offer ideal support settings that are hard to maintain in everyday life, and this shapes the ultimate results.Interestingly, Science Alert reported something new on the horizon—a daily pill in development works about as well as injectable semaglutide in helping people lose weight. In the highest dose group in early trials, people on this pill lost around 9.6 percent of their body weight. If these results hold up, it could add a convenient and more widely accessible way for people to benefit from GLP-1 based therapies.This surge in demand is partly fueled by how quickly weight loss happens for some people. A study of users in the United Kingdom taking tirzepatide found an average loss of 15 pounds in just six weeks, or almost four pounds per week. Medical experts still urge caution, emphasizing that lasting weight loss works best with changes to eating and activity alongside any medication.Latest research highlighted by Science Daily points to new brain targets that could lead to better GLP-1 therapies with fewer side effects, such as nausea, which remains the most common downside. Scientists hope this could someday mean drugs that deliver all the benefits of current treatments without the drawbacks, or even help address other conditions like addiction.These medications are not just for one group—eighteen percent of Black adults in the United States report trying a GLP-1 medication, compared to ten percent of White adults and thirteen percent of Hispanic adults. The use is most common among Americans aged fifty to sixty-four, both for weight loss and for chronic disease management.Costs remain a hot topic and can vary widely. While branded options tend to be expensive, the introduction of compounding pharmacies has altered the price landscape, though safety remains a concern.We are watching a revolution in how people manage weight and related health concerns. New medications are being developed, ongoing research is improving our understanding, and more people than ever are engaging with these options.Thank you for tuning in to Ozempic Weightloss Unlocked. Be sure to subscribe so you never miss the latest news in this fast-changing field. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic, the prescription drug originally developed to treat Type 2 diabetes, continues to generate headlines as one of the most discussed weight loss medications on the market. In the past week, the conversation has shifted back into public focus as new studies and high-profile personal stories further drive debate on its use and implications. According to Science Daily, researchers have underscored the impressive impact of GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro on significant weight loss. However, scientists highlight that there are still considerable unknowns when it comes to the long-term effects, especially as demand continues to surge among both diabetic patients and those seeking weight management solutions. They emphasize the critical need for more independent research to validate the safety and effectiveness of these drugs over time, cautioning against viewing them as a universal fix for weight issues.Amid the scientific scrutiny, public figures play a central role in shaping trends and personal attitudes toward weight loss medications. Oprah Winfrey's statements and her journey with weight loss drugs have been at the forefront of news coverage this week. She spoke candidly in a recent interview cited by OK! magazine about her experiences with weight fluctuations and the intense shame she internalized for decades. Winfrey admitted that after years of public and private struggle, she finally decided to seek a medically supervised course for her health, incorporating a weight loss medication into her routine in combination with hiking, dietary discipline, and a structured daily routine. As reported, although she did not publicly name the drug she uses, her remarks align with the widespread awareness of Ozempic, which remains frequently referenced in mainstream media when discussing celebrity weight loss.Winfrey's openness about her past resistance to medication due to feelings of inadequacy resonates with many. She acknowledged that she once felt compelled to prove she could lose weight through sheer willpower, rejecting medical intervention as a sign of failure. Her perspective shifted after recognizing that obesity is fundamentally a complex disease involving genetics and neurobiology. She now regards medically approved prescriptions as a legitimate tool, describing the medications as a “relief, redemption, and a gift.” Winfrey's reflection provides an alternative narrative to years of celebrity culture that equated body shape with personal virtue or discipline, stating that she is finished with the cycle of self-blame and external judgment.The cultural impact of Oprah's statements is amplified by the fact that, by her account, she has come to use these new medications largely to prevent the notorious “yo-yoing” phenomenon many people face with repeated weight loss and regain. Importantly, Oprah emphasizes that weight management is not about a number on a scale but about health, vitality, and quality of life. She continues to balance her use of the medicine with exercise and mindful eating, such as following Weight Watchers principles, hydrating adequately, and eating earlier in the day. Her story, widely covered by outlets including People magazine, has contributed to shifting the national conversation around both the legitimacy and the expectations of new weight management drugs.Meanwhile, the voice of the medical and scientific community remains cautious. They point out that, despite the clear short-term benefits observed in many users of Ozempic and similar drugs, long-term outcomes are unclear, and questions remain about side effects, sustainability, and the risk of weight regain if the drug is discontinued. As the number of people turning to Ozempic for weight loss continues to climb, especially in the wake of influential figures presenting medication as part of their success, researchers call for more systematic observation and independent study.In a recent personal milestone shared on social media, Oprah described completing a challenging hike she first attempted decades ago at a much higher weight, viewing the accomplishment as a powerful affirmation of her journey toward health more than any number on the scale. This symbolism, as reported in Parade magazine, captures a broader societal shift from focusing exclusively on weight to encompassing vitality, self-acceptance, and holistic wellness. With interest in Ozempic undiminished, stories like Oprah's underscore the nuanced convergence of medicine, celebrity influence, and public health messaging at a time when demand for effective weight management solutions is higher than ever.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

London's tech scene is awash with fresh investment as AI startups and fintech innovators pull in major funding rounds. We break down what this wave of cash means for the future of jobs and housing, amid London's booming AI ecosystem.Plus, AI data scraping battles are intensifying. With lawsuits flying, we speak to Fastly co-founder Simon Wistow about the escalating fight over how AI companies use online content.Also in this episode:Google releases Gemini 3, rolling advanced AI tools directly into SearchNASA tracks a rare interstellar comet as it passes through our solar systemPhysicsX, a London “physical AI” startup, has just extended its Series B to more than £117 millionLondon fintech SAPI raises £60m to support small businesses with flexible repayment tools.Rent-to-own platform Keyzy secures funding to buy £130m in homes for aspiring first-time buyersAll that, plus the latest from London's thriving tech and science scene, in today's Tech & Science Daily. Hosted on Acast. See acast.com/privacy for more information.

Ķīmija, lai arī bieži nemanāma un neuzkrītoša, ir klātesoša neskaitāmās mūsu dzīves jomās. Sākot ar produktiem mūsu vannasistabās un zāļu plauktos, beidzot ar enerģētiku un pārtikas drošību. Ķīmiķi Latvijā kopā ar fiziķiem šobrīd strādā pie nanopārklājumiem vēja turbīnu lāpstiņām un īpaša sensora, kas ziņotu par zivju produktu svaigumu. Par jaunākajiem pētījumiem raidījumā Zināmais nezināmajā stāsta Latvijas Universitātes (LU) asociētais profesors, Organiskās sintēzes institūta pētnieks, ķīmiķis Artis Kinēns un fiziķis no Ukrainas, LU Atomfizikas un spektroskopijas institūta vadošais pētnieks Romāns Viters. Stāstot par topošo zivju svaiguma kontroles sensoru, Artis Kinēns skaidro, ka pašreizējās tehnoloģijas, lai noteiktu pārtikas kvalitāti, bieži vien laboratorijas izmeklējumi. "Tas nozīmē, ka ir jāņem zivs paraudziņus, sūta uz laboratoriju, taisa mikrobioloģiskos testus. Tas aizņem labākajā gadījumā dažas stundas, realitātē - vairākas dienas. Tas nozīmē, ka tas svaigums, ko noteicāt, jau ir divas dienas vecs," norāda Artis Kinēns.  Otrs variants ir fizikālas metodes, kam nepieciešams fizisks kontakts ar zivi.  "Bet ko darīt, ja zivs ir iepakojumā? Ja atvērt iepakojumu vaļā, jau ir atkritums radies. Arī tad, ja zivs paraugu sūta uz laboratoriju, arī ir radīts atkritums. Līdz ar to nav labas tiešsaistes metodes, kurā būtu iespējams kontrolēt pārtikas produktu, kas jau ir iepakojumā, lai tas nebūtu jāatver." "Galvenā priekšrocība, ko redzam pret klasisko derīguma termiņu, jo arguments būtu, derīguma termiņš ir uzdrukāts, viss kārtībā. Bet derīguma termiņš nekādā veidā nepastāsta, kā tā zivs ir bijusi glabāta. Ja viņi ir pa ceļam vesta ar ķerrā, bez saldēšanas, tad viņa būs sabojāsies krietni ātrāk, nekā ir derīguma termiņš uzrakstīts. No otras puses, ja viņa ir glabāta korekti, tas derīguma termiņš arī varbūt nav korekts. Viņš vienkārši pasaka, ka šeit būs droši, ja mēs viņu metīsim ārā. Bet tikpat labi viņa ir lietojama vēl varbūt nedēļu," analizē Artis Kinēns. "Pateicoties tam, ka nav tāda ātra kontroles mehānisma, es teikšu diezgan šausmīgu statistiku, ka aptuveni 30% no saražotās zivju produkcijas tiek izmesta ārā tikai tāpēc, ka nenonāk līdz galapatērētājam laikā." Daļa šīs produkcijas noteikti vēl būtu lietojama, bet termiņš saka, ka ir jāmet ārā. "Inovācija būtu tāda, ka, ja mēs varam šo ieviest kā standarta praksi, ka mums ir iepakojums, kurā iekšpusē ir uzlīme, kurā ir iestrādāts luminofors, tad to no ārpuses var noskenēt vai nu ar kādu lasītājierīci, ideālā gadījumā mobilo telefonu, un tas pasaka: zivs vēl ir derīga tik un tik ilgu laiku," skaidro Artis Kinēns. Pētnieks norāda, ka šobrīd mērķis ir topošo sensoru un iespējas ar to veikt svaiguma mērījumus piedāvāt pārtikas izplatītājiem un pārtikas veikaliem, lai viņiem būtu iespēja labāk kontrolēt savu produktu plūsmu, lai tā samazinātu atkritumu rašanos.  "Viņu gadījumā tā ir mobilā telefona aplikācija, visticamāk, kura nofotografē uzlīmīti, kas ir  iekšpusē pie zivs pielikta, un no tās fotogrāfijas viņš nolasa zivs svaigumu," atzīst Artis Kinēns. "Ja runājam par patērētājiem, tad pielietojums varētu būt ļoti līdzīgs - ar mobilo  telefonu nofotografē zivi veikalā un lietotne pasaka, ka zivs ir derīga vai nav." Zinātnes ziņas Ziemā vērts vakariņas ēst agrāk Laikā, kad ārā agri paliek tumšs, izrādās, ka ir vērts pārskatīt mūsu vakariņu paradumus un ieturēt maltīti agrāk! Pētnieki no Džona Hopkinsa universitātes analizējuši sasitību starp mūsu iekšējo pulksteni un vielmaiņu un secinājuši, ka ēdot vakariņas ziemā agrāk, mēs palīdzam savam organismam labāk pārstrādāt uzņemto pārtiku. Arī dzīvnieki var sirgt ar hiperaktivitātes sindromu Cilvēku pasaulē ir tik ierasti runāt par tādām diagnozēm kā autisms, arī uzmanības deficīta un  un izskatās,  ka arī daži mūsu mājdzīvnieki varētu sirgt ar līdzīgām kaitēm. Tas tāpēc, ka pie vainas abos gadījumos ir strukturālas un ķīmiskas izmaiņas smadzenēs. Pētnieki noskaidorjuši, ka, piemēram, suņiem, žurkām, pelēm un atsevišķiem primātiem var būt izmaiņas gēnos, kas saistītas ar hiperaktīvu un impulsīvu uzvedību. Regulāra mikroplastmasas lietošana paātrina aterosklerozes veidošanos Kalifornijas universitātes pētnieki papildinājuši mūsu zināšanas par mikroplastmasas ietekmi uz cilvēka organismu. Eksperimentos ar pelēm, atklāts, ka regulāra mikroplastmasas lietošana paātrina aterosklerozes veidošanos. Ateroskleroze ir stāvoklis, kad sašaurinās artērijas, radot lielāku insulta vai infarkta risku. Te gan jāpiebilst, ka pētījumā šādus rezultatus uzrādīja tieši peļu tēviņi nevis mātītes. Abu dzimumu peles baroja ar zemam holesterīnam labvēlīgu diētu, taču regulāri deviņu mēnešu laikā pelēm tika iebarota arī mikroplastmasa atbilstoši dzīvnieku svaram.  E.coli baktērijas izplatība ir tikpat ātra kā cūku mērim Tīmekļa vietnē “ScienceDaily” ar pirmpublikāciju zinātnes žurnālā “Nature Communications” nonācis raksts par kādu zarnu baktērijas jeb Escherichia coli īpašību. Zinātnieki no Somijas un Norvēģijas pirmo reizi ir novērtējuši, cik ātri E.coli baktērijas var izplatīties starp cilvēkiem, un, kā izrādās, viens šīs baktērijas celms izplatās tikpat ātri kā cūku gripa. Pētnieku darbs piedāvā jaunu veidu, kā uzraudzīt un kontrolēt pret antibiotikām izturīgas jeb rezistentas baktērijas. Antimikrobiālā jeb antibiotiku rezistence ir aktuāla problēma veselības aprūpē, un tieši šonedēļ līdz 24. novembrim aizrit Pasaules antimikrobiālās rezistences izpratnes nedēļa. Tāpēc par baktērijas izplatību, bīstamību un, protams, ārvalstu pētnieku paveikto saruna ar Eiropas Pārtikas nekaitīguma iestādes valdes priekšsēdētāju, kā arī Pārtikas drošības, dzīvnieku veselības un vides zinātniskā institūta “BIOR” zinātniskās padomes priekšsēdētāju Aivaru Bērziņu.   

This Week on the Pod: Rain, Parades, Hive Minds, and… Ben's Brain for Rent? This week's episode opens with a very rainy round of real-life updates. Ben has been slammed with work and declares—formally, officially, irrevocably—that poetry is better than parades. (He is fully prepared to defend this position.) Meanwhile, Steven reports that the local parade and festival still happened despite the rain, because sometimes community spirit just refuses to check the weather. And Devon? He keeps forgetting that he's technically a Texan now, which raises several questions about residency, identity, and barbecue obligations. But the week wasn't all jokes—Ben also shared the sad news that Orion has passed. He was a very good boy, and the pod raises a collective toast. Ben's been spending time catching up on life, trying to relearn what "rest" even means, and also casually dropping the bomb that Affinity is now free. (Yes, really—go see for yourself at affinity.studio.) And while you're browsing, you can apparently rent Ben's actual mind at Penciledin.com, which sounds like a threat but is, in fact, a service. Steven also let us know that the Fallout Season 2 trailer is out, so it's time to emotionally prepare for more post-apocalyptic chaos.  Future or Now: Tylenol, Autism, and the Psychology of Hive Minds Devon kicks off this segment with actual real science: new research shows no clear link between acetaminophen (Tylenol) and autism, which is a big deal considering how long that concern has been floating around. (Links to ScienceDaily and the BMJ included in the show notes for the skeptics and science nerds.) Then we collectively decide: yes, we need to talk about Plur1bus. And we go deep. This is a full-spoiler discussion, so skip ahead if you're still watching. We cover everything—from the protagonist who's also the antagonist, to the messy moral math of a hive mind, to Devon's incredibly passionate speech about wanting to understand hive-mind psychology. Steven brings up that Internet-as-proto-hivemind theory, and Ben drops several very good points as per tradition. If you want episode breakdowns, the Wikipedia page has everything laid out neatly and also serves as a reminder that this show is way smarter than any of us expected when we hit "play." Book Club (Sort Of) We skipped Book Club this week because there was simply too much Plur1bus to process. Next week: We're reading City Grown From Seed by Diana Dima. Content warning: domestic violence / domestic abuse. You can read it for free on Strange Horizons.

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Hey Pickles!We hope you're doing well!Here's what's coming up in today's show!In this week's Y Files, could sunflowers be the future of vegan meats?Here's the article from Science Daily: https://www.sciencedaily.com/releases/2025/11/251104013006.htmIn our Noteworthy segment, Miyoko Schinner is trying to buy back her vegan creamery. We'll update you on the situation.And, in Our Main Topic, we discuss the hidden mental toll on animal farmers.Here's a link to the study: https://bryantresearch.co.uk/insight-items/farmer-mental-health/Our featured Vegan spot in our Assignment Restaurant SOS this week is Not Ya Mama's Vegan Cafe in Salem, Massachusetts.Check out their menu here: https://notyamamascafe.com/menuOf course we have a new Listener Shout Out and more!Thanks so much for listening. Much love, Sam & ChristineSend us a text! We can't respond, but we'd love to hear from you!Support the showJoin Our Patreon https://www.patreon.com/CompassionandcucumbersSign Up For Our Newsletterhttps://www.compassionandcucumbers.comOur YouTube https://www.youtube.com/@compassioncucumbersveganpod/videos72 Reasons To Be Vegan *paid link https://amzn.to/3W8ZwsUVisit Our Website https://www.compassionandcucumbers.comSam's Etsy https://www.etsy.com/shop/CucumberCraftworks

Real Life It's another week of real life, questionable decisions, and sci-fi tangents. Does Devon Even Like Being on the Show? We ask the question no one dared to before—and yes, Devon does like being here. Just… maybe not for the reasons you think. Ben's Apology Tour Continues Ben kicks things off with an immediate apology for this podcast. Again. But he makes up for it by diving into Apple TV's The Big Door Prize (IMDb link)—a show full of mysteries, midlife crises, and a machine that tells you your true potential. He's also been watching Zen for Nothing and Piece by Piece, and we learn something shocking: Steven hates LEGO. Steven's Space Drama Speaking of Steven, he's wrestling with another defeat in Shatterpoint (at the hands of Christina's husband, again), and somehow this leads to him buying a Camtono. Why does he have one? No one knows. But we do get a heated debate about the LEGO Enterprise and whether Ensign Ro or Tasha Yar had the raw deal in Star Trek. Devon's Hive-Mind Obsession Devon's been watching Plur1bus on Apple TV and can't stop talking about how eerily well it captures collective consciousness. For a guy who insists he's an individual, he sure sounds like part of a hive. Future or Now Ben actually brings good news this time. Seriously. His pick is a hopeful piece on how Solarpunk is already happening in Africa—how communities there are skipping the outdated infrastructure of the past and heading straight into a sustainable, decentralized future. Read it here: Why Solarpunk Is Already Happening in Africa   Meanwhile, Steven turns up the heat—literally—with a wild story out of Death Valley. Scientists studying Tidestromia oblongifolia found it doesn't just survive in brutal heat—it adapts on the fly, rearranging its cells and genes to keep photosynthesizing when everything else would fry. It's a real-life lesson in evolution under pressure. (ScienceDaily link)   Book Club This Week: In the Forests of Memory by E. Lily Yu (read here) – a haunting, quiet story about memory, commerce, and humanity told through the eyes of a trader and a stranger. It's as poetic as it is unsettling. Next Week: City Grown From Seed by Diana Dima (read here) – content warning for domestic violence and abuse. It's an eerie, metaphorical story that we'll unpack next episode. Between Ben's apologies, Devon's hive talk, and Steven's LEGO rage, it's another week of chaos, sci-fi, and accidental enlightenment. You can listen to the full episode wherever you get your podcasts—or watch our faces slowly melt under studio lights on YouTube.

Today, Jenny and Mr. John dig into some new research and more real talk yet again! From optimal resistance training or results to ultraprocessed foods and putting an end to type 1 diabetes, the research is coming in hot! And don;t miss John's Real Talk about education in the fitness fields- it comes in many shapes and ways! Happy listening!References: 1. Comparable Strength and Hypertrophic Adaptations to Low-Load and High-Load Resistance Exercise Training in Trained Individuals: Many Roads Lead to RomeKristoffer Toldnes Cumming, Ingrid Cecelia Elvatun, Richard Kalenius, Gordan Divljak, Truls Raastad, Niklas Psilander, Oscar Horwath bioRxiv 2025.04.28.650925; doi: https://doi.org/10.1101/2025.04.28.6509252. Samuel J. Dicken, Friedrich C. Jassil, Adrian Brown, Monika Kalis, Chloe Stanley, Chaniqua Ranson, Tapiwa Ruwona, Sulmaaz Qamar, Caroline Buck, Ritwika Mallik, Nausheen Hamid, Jonathan M. Bird, Alanna Brown, Benjamin Norton, Claudia A. M. Gandini Wheeler-Kingshott, Mark Hamer, Chris van Tulleken, Kevin D. Hall, Abigail Fisher, Janine Makaronidis, Rachel L. Batterham. Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic health: a randomized, crossover trial. Nature Medicine, 2025; DOI: 10.1038/s41591-025-03842-03. Mayo Clinic. "This sugar molecule could stop type 1 diabetes, by fooling the immune system." ScienceDaily. www.sciencedaily.com/releases/2025/08/250802022917.htm (accessed August 2, 2025).

Welcome to Ozempic Weightloss Unlocked, where we break down the most up-to-date stories in the world of Ozempic, from healthcare breakthroughs to the cultural waves reshaping how we think about weight loss. I am glad you are here.Let us dig into one of the biggest developments making headlines: a national Gallup survey just revealed that the United States is seeing a real decrease in adult obesity rates for the first time in years. This is not just a blip. Experts are linking the trend to the rapid rise in use of GLP-1 medications like Ozempic. According to Healthline and CBS News, the number of Americans using these injectables for weight loss has more than doubled in just the past year, with about twelve percent now reporting current use. Women are leading the charge in use and have seen slightly bigger drops in obesity rates compared to men.The story does not stop with adults. Think Global Health points out that Ozempic and similar drugs are being prescribed more frequently to adolescents, with use in children and teens increasing by nearly six hundred percent over the last five years. This surge follows Food and Drug Administration approval for ages twelve and up, but experts caution that pediatric guidelines and global access remain uneven.Back to the grown-ups: age seems to be a key factor. According to Gallup's analysis, adults between forty and sixty-four years old are using these medications most and have had the greatest reductions in obesity rates. Meanwhile, older Americans show higher rates of using these drugs but do not see as big an impact on their obesity numbers.Now, what is happening in the body when someone takes Ozempic? These medications work by mimicking hormones in the gut that help control appetite. They make you feel full longer, reduce hunger, and even curb cravings for fatty foods. The result is, as Medical News Today explains, many people lose meaningful weight — and maintain improvements in blood sugar, blood pressure, and cholesterol levels.But here is something that might surprise you. According to a large international study led by University College London and shared in Science Daily, Ozempic does not just help with weight. It reduces the risk of heart attack and stroke by about twenty percent, even for people who do not lose a lot of weight while on the drug. Researchers saw these heart benefits for people across a range of body types. The study found that a reduction in waist size did explain some of the improvement in heart health, but a full two-thirds of the benefits seemed unrelated to weight loss alone, which suggests Ozempic may support heart health through other mechanisms.Let us talk long-term results, because listeners want to know what happens after the initial weight loss. New research shared in the Cochrane Database of Systematic Reviews and reported by major health outlets compared Ozempic to other leading medications. Drugs like Mounjaro helped patients lose up to sixteen percent of their body weight over twelve to eighteen months and keep it off for as long as three and a half years. For Ozempic, the sustained weight loss averaged eleven percent over sixteen months, with benefits lasting for around two years. All of these drugs outperformed older medications in long-term trials.However, experts say it is important to be aware of the whole picture. Like all medications, Ozempic and similar drugs come with side effects. The most common are digestive issues like nausea, constipation, or diarrhea, along with headaches and abdominal pain. Fatigue can occur too. And doctors stress that weight management with these drugs is not quick or effortless. It is a long-term process that requires commitment to healthy habits in diet and movement for the results to last.One final thought: as usage spreads, voices like the Pew Research Center note that most Americans now see these medications as a good option for people with true weight-related health issues. Still, a sizeable stigma remains about using them for non-medical reasons.Thank you for tuning in to Ozempic Weightloss Unlocked, where the science and stories making headlines come straight to your headphones. Do not forget to subscribe for all the latest news on Ozempic and its impact on health, lifestyles, and beyond.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Welcome to the Refill! Refilling your mind with the latest in mental health and Pharmacy news.This is a new channel (and podcast segment), designed to bring you the latest insights and news in the world of mental health and pharmacy. If you want more tips and conversations about mindfulness, and mental health checkout The Mindful PharmD Podcast on major podcast platforms.Connect with me --> https://drmatmonharrell.bio.link/Music provided by PodcastleReferencesThe Hebrew University of Jerusalem. Popular hair-loss pill linked to depression and suicide. ScienceDaily. October 13, 2025. Available from: https://www.sciencedaily.com/releases/2025/10/251013040343.htmUnknown Author. (2025). Simple screening tool could save a patient's life. Doximity. https://www.doximity.com/articles/7e2b43ef-176d-44ac-ad43-1b857e092232Kansteiner F. With FDA nod, Bayer's Lynkuet enters US market for nonhormonal menopause symptom meds. FiercePharma. October 24, 2025. Available from: https://www.fiercepharma.com/pharma/fda-nod-bayers-lynkuet-enters-limited-us-market-nonhormonal-menopause-symptom-meds Vincent, E. & Vincent, B. (2025, October 20). Instagram shows more ‘eating disorder-adjacent' content to vulnerable teens, internal Meta research shows. Reuters. https://www.reuters.com/business/instagram-shows-more-eating-disorder-adjacent-content-vulnerable-teens-internal-2025-10-20/ Subscribe. Share. Rate.A thousand thanks!drmatmonharrell.bio.link Hosted on Acast. See acast.com/privacy for more information.

Découvrez comment, partis des steppes pontiques, les Yamnayas ont laissé leur empreinte dans nos langues, nos gènes et notre culture. Cette grande migration indo-européenne a bouleversé la préhistoire : entre fusion des peuples, échanges culturels et héritage durable, les Indo-Européens ont refaçonné l'Europe. #génétique #archéologie Retrouvez le script, la bibliographie complète et les crédits sonores et graphiques sur : https://ladentbleue.fr/migration-indo-europeenne-europe-yamnaya-ceramique-cordee Suivez La Dent Bleue sur :

Baltijas stipendija sievietēm zinātnē šogad piešķirta trīs latviešu zinātniecēm, kuras darbojas kvantu fizikā, precīzijas medicīnā onkoloģijā un laikmetīgās mākslas pētniecībā. No laboratorijām līdz mākslas galerijām - saruna ar pētniecēm studijā. Raidījumā Zināmais nezināmajā sarunājas Rīgas Stradiņa universitātes Sociālo zinātņu fakultātes vadošā pētniece Jana Kukaine, Latvijas Universitātes fizikas doktorante Elīna Pavlovska un Latvijas Biomedicīnas pētījumu un studiju centra pētniece Monta Brīvība. Bioloģijas zinātņu doktorei Montai Brīvībai 2025. gada Baltijas valstu stipendija sievietēm zinātnē piešķirta par pētījumu “Precīzijas medicīna onkoloģijā”. Humanitāro zinātņu doktorei Janai Kukainei 2025. gada Baltijas valstu stipendija sievietēm zinātnē piešķirta par pētījumu “Augu estētika Baltijas laikmetīgajā mākslā: sieviešu stāsti un pieredze”. Doktora grāda kandidātei Elīnai Pavlovskai 2025. gada Baltijas valstu stipendija sievietēm zinātnē piešķirta par pētījumu “No divdaļiņu sadursmēm līdz kolektīviem stāvokļiem: elektronu korelāciju analīze mezoskopiskos kolaideros”. Un vēl zinātnes ziņas Šoreiz zinātnes ziņās, skatot mazliet vairāk nekā tikai virsrakstu līmenī, mūsu uzmanības lokā nonākusi publikācija vietnē “Science Daily”. Tajā vēstīts par nanotehnoloģiju, kas pārveido etiķi par dzīvību glābjošu superbaktēriju iznīcinātāju.  Precīzāk - zinātnieku komanda no Norvēģijas un Austrālijas ir uzlabojuši etiķa antibakteriālās īpašības, pievienojot tam kobalta un oglekļa nanodaļiņas. Šis ar nanodaļiņām pastiprinātais šķīdums iznīcina kaitīgās baktērijas gan šūnu iekšienē, gan ārpus tām, vienlaikus saglabājot drošību cilvēkiem. Testi ar pelēm parādīja, ka šķīdums efektīvi dziedē inficētas brūces, un šis atklājums varētu būt izrāviens cīņā pret antibiotikām rezistentām baktērijām, kas izraisa infekcijas visā pasaulē. Komentāru par šo sniedz Latvijas Universitātes Medicīnas un dzīvības zinātņu fakultātes asociētais profesors, vadošais pētnieks Latvijas Universitātes Mikrobioloģijas un biotehnoloģijas institūtā Jānis Liepiņš. Vai viņam, lasot šo publikāciju, ir prieks par šādiem jaunumiem vai varbūt par kaut ko ir šaubas un piesardzība? 

Experts are warning that women are being exploited by a growing ‘menopause gold rush' as companies and influencers rush to give profit-driven advice.It's led to a call for a national education programme to ensure women get clear, evidence-based support and advice.Meanwhile, UK scientists are hoping to join NASA in working on the Habitable Worlds Observatory - a new telescope designed to search for signs of life on distant planets.We hear from Dr Vincent Van Eylen, Associate Professor in Exoplanets at UCL's Mullard Space Science Laboratory about the project and what it means for the UK's role in future space exploration.Also in this episode:AI could give NHS staff back 400,000 hours a monthMPs are questioning why UK's key online services rely on Amazon after yesterday's major outageSpace debris that has fallen to Earth is thought to be from a Chinese rocketMicrosoft confirms next-gen Xbox is in developmentBingo, holidays and meals out are helping older men stay stronger for longerHear Rachelle Abbott's interview about the AWS outage from yesterday's Tech & Science Daily. She speaks with Antonio Weiss, a Senior Partner at The Public Services Consultants, and former Senior Digital Adviser to Sir Keir Starmer, about the internet disruption. Hosted on Acast. See acast.com/privacy for more information.

A huge internet outage caused widespread global disruption on Monday, with a number of major websites and apps experiencing significant service issues.The issue was linked to a problem on cloud computing provider, Amazon Web Services (AWS). Major organisations such as HMRC, Lloyds Bank, Ring Doorbell, Snapchat, Slack, and Fortnite were among those affected, with outage monitoring website Downdetector reporting a massive spike in errors, 6.5 million in total worldwide.Tech & Science Daily spoke to Sir Keir Starmer's former Senior Digital Adviser, Antonio Weiss, who is now a senior partner at The Public Services Consultants.Also in this episode:-Why European astronauts are training to fly helicopters ahead of lunar missions…-Alongside Cate Blanchett, The King has hailed the work of Kew Gardens' Millennium Seed Bank 25 years after it opened-Birth of rare female eastern mountain bongo is a ‘significant milestone' for species Hosted on Acast. See acast.com/privacy for more information.

It's another week in real life for the gang — or at least for most of us. Devon's down sick, so it's a two-man show featuring Steven and Ben navigating the bizarre crossroads of tech, food, and VR golf.

Šakāļi māju pagalmos, caunas, kas pārgrauž automašīnu vadus, ezis, kas ziemas migu uztaisījis komposta kaudzē, un lapsas, kas siro pa atkritumu konteineriem. Cilvēka tuvumā dzīvnieki atraduši sev gana piemērotu vietu, lai dzīvotu. Kāpēc mūsu tuvums dzīvniekiem ir noderīgs un kā sadzīvot ar savvaļu uz mājas sliekšņa? Raidījumā Zināmais nezināmajā sarunājas Rīgas Nacionālā Zooloģiskā dārza pārstāvis Māris Lielkalns, Latvijas Nacionālā Dabas muzeja pārstāve, zooloģe Inta Lange un zoologs Vilnis Skuja.   Zinātnes ziņas Nobela prēmija fizioloģijā vai medicīnā 2025 Šis ikgadēji ir Nobela prēmiju laureātu paziņošanas periods. Tieši pirms nedēļas raidījumā runājām par imunitāti un imūnsistēmu, un arī Nobela prēmija fizioloģijā vai medicīnā šogad pasniegta trim pētniekiem - amerikāņu zinātniekiem Mērijai Brankovai un Frederikam Ramsdelam, kā arī japāņu zinātniekam Šimonam Sakaguči - par atklājumiem imūnsistēmas kontroles jomā, proti, par to, kā imūnsistēma tiek pasargāta no uzbrukumiem mūsu pašu ķermenim un orgāniem.  Džeina Gudola mainīja mūsu priekšstatu par pērtiķiem Mūžs, kas veltīts zinātnei, var vainagoties ar Nobela prēmiju, bet vēl viens vienreizējs mūžs noslēdzās pagājušajā nedēļā. Runa ir par ievērojamo primatoloģi, šimpanžu pētnieci, Džeinu Gudolu, kura pagājušajā nedēļā 91 gada vecumā devās mūžībā, bet viņa sniegusi lielu ieguldījumu mūsu priekšstatos par pērtiķiem. Tāpēc visas nedēļas garumā tīmeklī aizvien parādās raksti par Gudolas dzīvi un darbu. Vai jūs ēstu jogurtu, kas gatavots ar skudrām? Zinātnieki to izdarīja Kukaiņi var ne vien kaut ko sadalīt vai noārdīt, bet arī radīt, un tie var radīt jogurtu. “Vai jūs ēstu jogurtu, kas gatavots ar skudrām?” - tāds jautājums tiek uzdots “ScienceDaily”, piebilstot, ka zinātnieki to ir pamēģinājuši.  Apvienojot zinātni un tradīcijas, pētnieki ir atdzīvinājuši senu Balkānu un turku jogurta gatavošanas tehniku, kurā skudras tiek izmantotas kā dabiski fermentētāji. Skudru baktērijas, skābes un enzīmi pārveido pienu bagātīgā, pikantā jogurtā, vienlaikus demonstrējot daudzveidību un sarežģītību, kas dažkārt zūd mūsdienu industrializētajās jogurta šķirnēs. Eksosomu zinātne - jaunākā apsēstība ādas kopšanā Eksosomas ir nanoizmēra daļiņas, ko izdala lielākā daļa šūnu veidu un kas tiek slavētas par to atjaunošo spēku cilvēka organismā, tostarp par signālu sniegšanu, kad ražot vairāk kolagēna. Eksosomu serumi šobrīd ir kļuvuši ļoti populāri ādas kopšanas jomā, arī sociālajos medijos tie tiek ļoti popularizēti, tomēr eksperti mudina ievērot piesardzību un nepārvērst eksosomas par apsēstību.    

On this replay preview of Brave New World, Evgeny Lebedev is in conversation with the Oscar-winning actor, Dame Helen Mirren.Now, this is a bit of a break from the usual guests on Tech & Science Daily, but in this wide ranging conversation Evgeny and Dame Helen discuss everything from the evolution of technology, ageing, to the contemporary media landscape and social media.“It's so sad that Kurt Cobain died when he did, because he never got to see GPS”Listen to the full conversation on the Brave New World podcast here. Hosted on Acast. See acast.com/privacy for more information.

Earlier this year, scientists at Oxford University Physics revealed that they've made a breakthrough in quantum computing by demonstrating the first instance of distributed quantum computing. They linked two separate quantum processors using a photonic network interface to form a single, fully connected quantum computer. Science Daily explains that this approach addresses the "scalability problem" of quantum computers, which would require immense size to process millions of qubits. You can listen to all of the Quantum Minute episodes at https://QuantumMinute.com. The Quantum Minute is brought to you by Applied Quantum, a leading consultancy and solutions provider specializing in quantum computing, quantum cryptography, quantum communication, and quantum AI. Learn more at https://AppliedQuantum.com.

Turpinām iepazīt Latvijas dabu, šoreiz saruna par kādiem īpaši aizsargātiem nakts dzīvniekiem, bez kuriem nav iedomājami vecu māju pagrabi vai bēniņi - sikspārņiem. Šie neparastie dzīvnieki gan burtiskā, gan pārnestā nozīmē dzīvo kājām gaisā - tie pasauli sadzird nevis saredz un par savu ērtāko un komfortāko vidi uzskata tās vietas, no kurām cilvēks labprātāk vairās - tumšus pagrabus, alas, bēniņus un pamestas ēkas. Kā Latvijā klājas sikspārņu sugām, kura ir Latvijas sikspārņu galvaspilsēta un ko zinām par sikspārņiem piemītošo prasmi - eholokāciju? Raidījumā Zināmais nezināmajā iepazīstina Latvijas Universitātes Bioloģijas institūra pētnieks, sikspārņu pētnieks Viesturs Vintulis un ihtiologs Ivars Putnis.   Raidījuma noslēgumā zinātnes ziņas Pirmdienas tiešām ir nogurdinošākas smadzenēm un ķermenim. Ne viens vien cilvēks, sākot jaunu darba nedēļu pirmdienā, būs nodomājis, cik pirmdienas ir grūtas dienas. Gadu desmitiem lietots arī apzīmējums “pirmdienas nomāktība” jeb angļu valodā “Monday blues”, kas kopumā raksturojis smagnēju sajūtu katras jaunas darba nedēļas sākumā. Bet par to visu iespējams runāt arī no medicīnas un psiholoģijas skatpunkta, un par to raksta “Scientific American”. Miljoniem cilvēku pasaulē nezina, ka viņiem ir cukura diabēts. Par to vēsta “Science Daily”. Mākslīgā intelekta asistents Albānijā kļuvis par “ministru”. Aizvadītās nedēļas laikā viena no mediju lappusēs bieži fiksētām ziņām bijusi par to, ka Albānijas premjerministrs Edi Rama iecēlis pasaulē pirmo mākslīgā intelekta ģenerēto ministru, kurš pārraudzīs publiskos iepirkumus, lai novērstu korupciju. Ministra vārds ir “Diella”, un albāņu valodā tas nozīmē “saule”. Par šo var lasīt vietnē “Kursors.lv” un citos avotos. Sarunu boti, kas apgalvo, ka ir Jēzus: evaņģēlija sludināšana vai ķecerība? Par to var lasīt vietnē “Nature”.

Welcome to Ozempic Weightloss Unlocked, your source for the latest news, research, and insights on Ozempic and its impact on weight loss, health, and lifestyle.If you are following updates on Ozempic, recent international studies are shedding a spotlight on why so many are both drawn to and dropping away from this buzzy medication. According to reports from HealthDay and Drugs.com, about half of the adults who start Ozempic for weight loss end up quitting within just one year. For context, a study out of Denmark tracked more than seventy-seven thousand new Ozempic users and found that fifty-two percent gave it up before the year's end. These findings were presented at this year's European Association for the Study of Diabetes meeting in Vienna.So, why are so many discontinuing Ozempic? One major reason is cost. In Denmark, the lowest possible annual dose is over two thousand euros. In the United States, prices can jump to more than one thousand four hundred dollars monthly if uninsured. People in lower-income areas were nearly fifteen percent more likely to quit early. For many, the price tag is simply not sustainable long-term.Side effects are another factor. Drugs.com highlights that those with gastrointestinal conditions, chronic illnesses, or who are taking psychiatric medication are more likely to stop using Ozempic. The Danish study found that people with existing GI issues were nine percent more likely to quit, and those with heart disease or other chronic conditions were ten percent more likely to stop. Furthermore, common side effects like nausea, vomiting, and diarrhea disproportionately drive users to discontinue.Age and gender play a role too. Younger adults were forty-eight percent more likely to stop Ozempic within the first year compared to older users. Men had a twelve percent greater likelihood than women to quit. The study authors note that women tend to see slightly better weight loss results, which might help motivate their continued use.One important medical application is for people living with diabetes. Originally, Ozempic and similar drugs were developed to help manage blood sugar. However, they've gained popularity strictly for weight loss, and over ninety percent of new prescriptions in some studies are written for those without diabetes.Another recent clinical trial, reported by TheJournal.ie, looked at bumping up the standard dose to see if results improve. By tripling the weekly dosage to seven-point-two milligrams, nearly half of trial participants lost at least twenty percent of their body weight. But remember, higher doses may also lead to more side effects and costs.For younger women who are considering Ozempic, caution is warranted. According to researchers at Flinders University, there are hidden reproductive risks for women in their childbearing years. The Medical Journal of Australia reports that most women prescribed Ozempic are not using effective contraception, even though these medications can pose risks during pregnancy and fetal development. Only twenty-one percent of women on Ozempic were using contraception in one large study of more than one-point-six million general practice records. Notably, women with polycystic ovary syndrome were twice as likely to conceive after starting Ozempic, possibly because weight loss can improve fertility. Lead researcher Associate Professor Luke Grzeskowiak states the need for proper counseling on reproductive risks for women starting these drugs.A final point from ScienceDaily is that stopping Ozempic often leads to regaining weight. Because the drug works by curbing appetite and promoting the feeling of fullness, these benefits disappear once you stop. For most, it is not a quick fix but a long-term commitment.As awareness rises, so does the number of questions around cost, access, side effect management, and the balance of risks and benefits. Whether you are considering Ozempic, currently taking it, or simply curious about its role in the future of weight management, keeping up with peer-reviewed research and evolving guidelines from health agencies is crucial.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please remember to subscribe so you do not miss our next update. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

We know employers want creative thinkers. We know creative thinking is necessary to solve the problems we see everywhere in our world. We know we want our students to learn to be more creative.  But what does that mean exactly? Where does the science of creativity meet the cultural definition we all build for ourselves just by swimming in the 21st century stream? My guest today is Dr. Zorana Ivcevic Pringle. Let me share her bio with you: "With more than 25 years as a scientist studying creativity, Zorana brings insights into the nature of the creative process, from the first decision to engage with new ideas to its culmination in creative performances and products. She is a scientist at Yale University, author, and speaker. Zorana's work has been featured in the Harvard Business Review, ArtNet, US News, Education Week, Science Daily, El Pais, and others, and she is a regular contributor to Psychology Today and Creativity Post.” Today, we're talking about how science defines creativity, and how research shows us we can guide our students - and ourselves - to develop more creative confidence. You'll learn what's important in designing your space, launching and building creative units,  speaking with students about the hurdles that get in their path, and assessing creative work in a way that's meaningful for student development along the way, not just at the end. Honestly, I started Zorana's book, The Creativity Choice, searching for everything I could find to help me understand classroom creativity better. But I finished with fresh ideas not only for constructing curriculum and classroom spaces, but also for how I tackle projects, run my company, and talk to my own children about their ideas. Explore Zorana's Website: https://www.zorana-ivcevic-pringle.com/ Zorana's Substack: https://creativitydecision.substack.com/

California, what are you doing? Rain in the summer? Hail in Tahoe? Absolute chaos. At least Steven's chickens are thriving in this strange new climate—they've started laying eggs. A LOT of eggs. So many, in fact, that we're considering a new Patreon tier: Egg Delivery from Steven. Fresh, farm-to-door… assuming you live close enough for him to walk them over. Gaming Corner: From Voyager to Vaults Ben dove deep into nostalgia this week with a first look at the Star Trek: Voyager – Across the Unknown game. It's got exploration, it's got starships, it's got Janeway energy. Check it out for yourself: ▶ Trailer

The “China Study” is cited as evidence vegetarian diet is best—but big new study shows vegetarians age less well than omnivores; Can a popular men's health supplement ward off prostate cancer? MAHA officials hit pause on looming natural thyroid ban; Can diet alleviate symptoms of lipedema? Precision-engineering your gait can alleviate knee pain better than NSAIDs; After a lifetime of profound depression, novel brain implant enables man to experience joy for the first time.

A few weeks back I debunked five studies on priming. But did I get it wrong?  Today's guest on Nudge thinks I missed something.  Tune in to hear consumer behaviour expert Philip Graves explain his view on priming.  --- Phil's book: https://shorturl.at/kzAta Phil's consultancy: https://www.philipgraves.net/consultancy/ Subscribe to the (free) Nudge Newsletter: https://nudge.ck.page/profile  Connect on LinkedIn: https://www.linkedin.com/in/phill-agnew-22213187/  Watch Nudge on YouTube: https://www.youtube.com/@nudgepodcast/ --- Today's sources:  Li, W., Moallem, I., Paller, K.A. & Gottfried, J.A. (2007) Subliminal smells can guide social preferences, Psychological Science, 18(12): 1044-9. Plassmann, H., O' Doherty, J., Shiv, B., & Rangel, A. (2008) Marketing actions can modulate neural representations of experienced pleasantness, Proceedings of the National Academy of Sciences, 105(3). Spence, C., & Wang, Q. (2017). Assessing the impact of closure type on wine ratings and mood. Beverages, 3(4), 52. University of Georgia. (2008). Simple recipe for ad success: Just add art. ScienceDaily. Wansink, B., & van Ittersum, K. (2007, August 6). Bad wine can ruin a good meal [Press release]. Cornell University. Yoon, S.-O. & Simonson, I. (2008) Choice set configuration as a determinant of preference attribution and strength, Journal of Consumer Research, 35(2): 324.

Adult 'Nerds,' Rent-a-Grandma and Fringe Friends. That's what Paul Layendecker is BuZzin' about on The Daily BuZz!!See omnystudio.com/listener for privacy information.

Real Life This week, Steven finally found a superhero movie that didn't make him want to throw his popcorn at the screen. Superman (2025) has arrived, and according to him, it's the best take we've had on the character in years. No origin story nonsense, just straight into Supes doing good and being good. James Gunn gets it—Superman is an immigrant, a boy scout, and a damn firefighter (not a cop). The moral core is there, the cape looks good, and apparently, if you hate it, it's because it's “woke”? Whatever. Steven liked it. You probably will too. Meanwhile, Devon has been dodging storms, not floods. He lives far from the Texas chaos but has had his fair share of wet weekends. That hasn't stopped him from grinding away at backyard renovations. Fake grass is coming soon. In the process, he's tearing out ivy and ground brush—bad news for copperhead snakes, which are venomous, and good news for anyone walking around barefoot. Speaking of venom: Ben brings us the delightful fact that some birds are venomous. No, really. There are birds that store toxins from insects and plants and use them to defend themselves. The pitohui says hi. Nature is weird. More bird venom facts here. Devon also dove into evolution this week, thanks to a Hank Green video about the great leap from water to land. Turns out the hardest problem evolution ever solved might just be how to turn gilled swimmers into four-limbed land mammals. Spoiler alert: it involves lungs, fins, and a lot of time. Watch the video here. Ben, when not thinking about venomous birds, asked an important question: What do people do for fun in Palmdale? The answer, apparently, is “hang out near electrical poles.” He also recommends the board game The Red Dragon Inn for those nights when you're too tired to fight dragons and just want to drink with them instead. Game info here. Future or Now Only Steven showed up for this segment, and he brought ancient lion maulings. A new article from ScienceDaily describes a skeleton found in a Roman cemetery in York—with bite marks matching a lion's jaw. It's our first archaeological evidence of gladiator-style combat between a human and a lion, which is equal parts horrifying and fascinating. Steven points out that if curses were real, this would be prime material—digging up gladiator graves seems like an express ticket to ghost lion attacks. Book Club This week, we read The Last Question by Isaac Asimov, a story about entropy, immortality, the heat death of the universe, and one computer's ongoing existential crisis. Devon raises a solid point: the story's final punch line hits different if you grew up with the Judeo-Christian idea of divine creation. If not? It still works, but maybe not quite the same way. You could easily sub in other creation myths—or just throw in some Terminators and call it a sci-fi remix. Ben had Siri read him the story aloud via Mobile Safari and recommends the experience. Read it here or watch this animated version. Next week: There Will Come Soft Rains by Ray Bradbury, a classic tale of loneliness, technology, and automatic breakfast machines still flipping eggs long after humanity is gone. You can read the story here or listen to a reading. Oh, and if you missed it, Captain Kirk is coming back—sort of. He's being resurrected for Star Trek: The Last Starship, a new comic set in the far future. We have thoughts. Mostly confused ones.

Researchers from the University of Innsbruck and the University of Waterloo have successfully simulated a complete quantum field theory in more than one spatial dimension using a novel type of quantum computer. Science Daily reports that the team used a qudit quantum computer, which can store and process information using up to five values per carrier, to efficiently represent complex quantum fields. You can listen to all of the Quantum Minute episodes at https://QuantumMinute.com. The Quantum Minute is brought to you by Applied Quantum, a leading consultancy and solutions provider specializing in quantum computing, quantum cryptography, quantum communication, and quantum AI. Learn more at https://AppliedQuantum.com.

Dr. Zorana Ivcevic Pringle is a Senior Research Scientist at the Yale Center for Emotional Intelligence. Her work has been featured in the Harvard Business Review, US News, Science Daily, and others, and she is a regular contributor to Psychology Today and Creativity Post. Zorana studies many aspects of the creative process, including idea generation but also creative mindsets, creative self-efficacy, and the role of emotions in creativity. Her new book is called The Creativity Choice: The Science of Making Decisions to Turn Ideas into Action. She argues that creativity is a choice--not only choosing in some abstract general way, but she gives advice about how to make creative choices throughout the creative process, from the first idea to the development of the idea. In this interview, she talks about creative mindsets, creative self-efficacy, and harnessing and managing your emotions to maximize creativity. For more information: Zorana Ivcevic Pringle's web site Music by license from SoundStripe: "Uptown Lovers Instrumental" by AFTERNOONZ "Miss Missy" by AFTERNOONZ "What's the Big Deal" by Ryan Saranich Copyright (c) 2024 Keith Sawyer

Dr. Zorana Ivcevic Pringle shares the tools and strategies for seeing the creative process through from start to finish.— YOU'LL LEARN — 1) How to feel more confident taking risks 2) How to make creative blocks work in your favor 3) How to get the most out of AI for work Subscribe or visit AwesomeAtYourJob.com/ep1058 for clickable versions of the links below. — ABOUT ZORANA — With more than 25 years as a scientist studying creativity, Zorana brings insights into the nature of the creative process, from the first decision to engage with new ideas to its culmination in creative performances and products. She is a scientist at Yale University, author, and speaker. Zorana's work has been featured in the Harvard Business Review, ArtNet, US News, Education Week, Science Daily, El Pais, and others, and she is a regular contributor to Psychology Today and Creativity Post.• Book: The Creativity Choice: The Science of Making Decisions to Turn Ideas into Action • Website: Zorana-Ivcevic-Pringle.com — RESOURCES MENTIONED IN THE SHOW — • Study: “Discovery-oriented behavior and the originality of creative products: A study with artists.” by Mihaly Csikszentmihalyi and Jacob Getzels • Study: “When do startups scale? Large-scale evidence from job postings” by Saerom (Ronnie) Lee and J. Daniel Kim • Study: The power of the ‘be creative' instruction: A meta-analytical evaluation” by Xing Wei, Wangbing Shen, Haiying Long, Fang Lu • Book: The Courage to Create by Rollo May — THANK YOU SPONSORS! — • Strawberry.me. Claim your $50 credit and build momentum in your career with Strawberry.me/AwesomeSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Every left winger should have their eyes held open and be forced to watch this on repeat until it sinks in. BONUS EPISODES available on Patreon (https://www.patreon.com/deniersplaybook) SOCIALS & MORE (https://linktr.ee/deniersplaybook) WANT TO ADVERTISE WITH US? Please contact climatetownsponsorships@gmail.comDISCLAIMER: Some media clips have been edited for length and clarity. CREDITS Created by: Rollie Williams, Nicole Conlan & Ben BoultHosts: Rollie Williams & Nicole ConlanExecutive Producer: Ben Boult Editor: Laura ConteProducers: Daniella Philipson, Irene PlagianosArchival Producer: Margaux SaxAdditional Research & Fact Checking: Carly Rizzuto & Canute HaroldsonMusic: Tony Domenick Art: Jordan Doll Special Thanks: The Civil Liberties Defense CenterSOURCESAccounts, T. C. of P. (2023). Wind Power: Energy is Good for Texas. Comptroller.texas.gov.Alsaleh, A., & Sattler, M. (2019). Comprehensive life cycle assessment of large wind turbines in the US. Clean Technologies and Environmental Policy, 21(4), 887–903.California Energy Commission. (2023). 2023 Total System Electric Generation. California Energy Commission.Carpenter, S. (2020, September 5). Why The Oil Industry's $400 Billion Bet On Plastics Could Backfire. Forbes.Carter, L. (2021, June 30). Inside Exxon's playbook. Unearthed.Clarion Energy Content Directors. (2010, May 2). Dynamic Pricing and Key Challenges. Renewable Energy World.Climate Town. (2025, February 11). How Oil Propaganda Sneaks Into TV Shows | Climate Town. YouTube.Coates, T.-N. (2024). The Message. One World.Dammeier, L. C., Loriaux, J. M., Steinmann, Z. J. N., Smits, D. A., Wijnant, I. L., van den Hurk, B., & Huijbregts, M. A. J. (2019). Space, Time, and Size Dependencies of Greenhouse Gas Payback Times of Wind Turbines in Northwestern Europe. Environmental Science & Technology, 53(15), 9289–9297.Davis, C. (2024, June 3). Vistra Eyeing Natural Gas-Fueled Expansion Across Texas to Bolster ERCOT Grid. Natural Gas Intelligence.Drilled. (2018, September 11). S1, Ep3 | Weaponizing False Equivalence. Drilled.EIA. (2024, October 9). How much oil is consumed in the United States? - FAQ - U.S. Energy Information Administration (EIA). Eia.gov.Eliq. (2024, June 5). The complete Dynamic Pricing guide for energy retailers - Eliq. Eliq.Erickson, P., & Achakulwisut, P. (2012). How subsidies aided the US shale oil and gas boom. Stockholm Environment Institute.Fox News Clips. (2018, November 29). “That Was Me, People”: Obama Takes Credit for Oil Production Boom. YouTube.Gardiner, B. (2019, December 19). The Plastics Pipeline: A Surge of New Production Is on the Way. Yale E360.Green, M. (2021, December 7). Your socks are made with plastic and could be loaded with dangerous BPA. San Francisco Chronicle.Guardian News. (2019). “I never understood wind”: Trump goes on bizarre tirade against windmills [YouTube Video]. YouTube.Guezuraga, B., Zauner, R., & Pölz, W. (2012). Life cycle assessment of two different 2 MW class wind turbines. Renewable Energy, 37(1), 37–44.Haapala, K. R., & Prempreeda, P. (2014). Comparative life cycle assessment of 2.0 MW wind turbines. International Journal of Sustainable Manufacturing, 3(2), 170.Harris, J. (2024, November 28). Scene from Billy Bob Thornton's New Show Goes Viral as His “Landman” Character Savages Green Energy. The Western Journal.Hartke, K. (2017, July 5). “The Sideways Effect”: How A Wine-Obsessed Film Reshaped The Industry. NPR.Hookstead, D. (2025, January 14). “Landman” Goes Viral With Scene Crushing Woke Environmentalists | OutKick. OutKick.Imperative Podcasts. (2022). Boomtown - Chapter 3: Dust to DustInternational Energy Agency. (2024). World Energy Investment 2024. YouTube. Jack, S., & Masud, F. (2025, February 26). BP shuns renewables in return to oil and gas. BBC.Krauss, C., & Penn, I. (2022, June 7). Shell, the Oil Giant, Will Sell Renewable Energy to Texans. The New York Times.Kreil, E. (2024, March 11). United States Produces More Crude Oil than Any country, Ever - U.S. Energy Information Administration (EIA). Www.eia.gov.Malewitz, J. (2013, October 14). $7 Billion Wind Power Project Nears Finish. The Texas Tribune.McEwen, M. (2024, November 18). API runs ads to challenge “Landman” oil industry portrayal. Midland Reporter-Telegram.Murray, C. (2023, June 30). The McDonald's Grimace Shake's Viral (And Gruesome) TikTok Trend, Explained. Forbes.Nelson, J. (2024, November 27). “Landman” clip goes viral slamming renewable energy: “There is nothing clean about this.”. Fox News.NW, T. C. for R. P. 1300 L. S., Washington, S. 200, & info, D. 20005 telelphone857-0044. (2025). Oil & Gas Lobbying Profile. OpenSecrets.Oklahoma Oil & Natural Gas, & OERB. (2022, July 19). Petro Pete's Adventure - Big Bad Dream - OERB. OERB.Paramount Plus. (2024a, November 27). Landman | Tommy Explains Why Even Wind Turbines Depend on the Oil Industry (S1, E3). YouTube.Paramount Plus. (2024b, December 3). Landman | Q&A with Billy Bob Thornton. YouTube.PBOG. (2017, October 12). The Well That Launched the Permian - Permian Basin Oil and Gas Magazine. Permian Basin Oil and Gas Magazine.Peach, S. (2021, June 30). What's the carbon footprint of a wind turbine?. Yale Climate Connections.Pitsel, P. (2021, February 26). What about Wind Farms?. LinkedIn.Plastic Pollution Coalition Editor. (2024, September 17). Fracked Gas is Now a Growing Share of the Fossil Fuels Being Turned Into Plastics. Plastic Pollution Coalition.Rapier, R. (2024, December 26). U.S. Oil Production Shattered Records Again in 2024. OilPrice.com.Rassenfoss, S. (2023, August 16). Shale Wells Producing More Early On, Then Declining Faster Than Ever. JPT.Schechter, D. (2020, February 16). VERIFY: Does conservative Texas actually lead the U.S. in green energy?. WFAA.Science Daily, & Taylor & Francis Group. (2024, May 16). Wind farms can offset their emissions within two years. ScienceDaily.Statistia. (2019, September 3). Infographic: Wind Turbines Are Not Killing Fields for Birds. Statista Infographics.Texas Monthly, & Wallace, C. (2019). Boomtown Podcast. Texas Monthly.The Climate Denier's Playbook. (2023, July 11). You Owe Your Life to Oil & Gas. Spotify.The Joe Rogan Experience. (2020, September 2). Joe Rogan Experience #892 - Greg Fitzsimmons. JRE Podcast.The Joe Rogan Experience. (2024, January 4). Joe Rogan Experience #2083 - Taylor Sheridan. JRE Podcast.TotalEnergies. (2024). Wind, Solar and Hydro Power: Our Renewable Energy Activities in France at a Glance. TotalEnergies.com.Twitter, & @bonchieredstate. (2024, October 24). Every left-winger should have their eyes held open and be forced to watch this on repeat until it sinks in. X (Formerly Twitter).U.S. Energy Information Administration. (2025, May 6). U.S. Field Production of Crude Oil (Thousand Barrels per Day). Www.eia.gov.Valle, S. (2023, April 4). Exxon says its decarbonization business could outgrow oil, in multi-trillion market. Reuters.Wallace, C. (2019, May 29). The Permian Basin Is Booming With Oil. But at What Cost to West Texans?. Texas Monthly.Wikipedia Contributors. (2024, December 29). Stephens, Arkansas. Wikipedia; Wikimedia Foundation.Williams, R. (n.d.). Scrolling through Tiktok in his parents' bathroom [Feculent Fact Finding].Zadrozny, B. (2025, January 8). Zuckerberg's fact-checking rollback ushers in chaotic online era. NBC News.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week in the studio, I'm joined by Dr. Nick Barringer—Army Ranger, performance nutrition expert, and one of the sharpest minds in military and metabolic health. Together, we cut through the noise around today's most controversial nutrition topics. If you've ever felt whiplash trying to make sense of conflicting headlines, this episode is your science-based compass.What's really going on with artificial sweeteners like sucralose and aspartame? Are seed oils toxic—or just misunderstood? And what's the actual science behind popular supplements like creatine, testosterone boosters and fat burners?Dr. Barringer brings two decades of elite military and research experience to help us separate hype from evidence—while sharing real-world tools that help people perform, think, and feel better.We cover:Whether sucralose and other artificial sweeteners damage DNA or gut healthWhat to actually worry about with food dyes Seed oils, inflammation, and what most people get wrong about themProtein and carb dosing for people over 40 (and how to think about fiber and fat)Why creatine is still the most underrated supplement for muscle and brain functionTactical hydration tips (and how sweat composition varies with diet)Hidden risks in testosterone boosters and “fat burners”Practical takeaways for elite performance, healthy aging, and being stronger at any ageWho is Dr. Nick Barringer?Nick Barringer, PhD, is a Nutritional Physiologist with deep experience in both applied and academic settings. He directed the U.S. Military-Baylor Graduate Program in Nutrition, taught at West Point, and was the first active-duty dietitian to graduate U.S. Army Ranger School and serve with the 75th Ranger Regiment. He holds a PhD in kinesiology from Texas A&M, and his research on tactical nutrition has been featured in outlets like Science Daily and Men's Journal.This episode is brought to you by: ARMRA - Use code DRLYON for 15% off your first order → tryarmra.com/DRLYON Manukora - Use code DRLYON for $25 off the Starter Kit → manukora.com/DRLYONOneSkin – Get 15% off with code DRLYON → OneSkin.coNed - 15% off with code DRLYON → helloned.com Find Nick Barringer at: LinkedIn - https://www.linkedin.com/in/nick-barringer-phd-rdn-cscs-cssd-5137789a/Instagram - https://www.instagram.com/nickbarringer.phd.rdn/Facebook - https://www.facebook.com/nickbarringer.phd.rdn/Find me at:Instagram: @drgabriellelyonTikTok: @drgabriellelyonFacebook: facebook.com/doctorgabriellelyonYouTube:youtube.com/@DrGabrielleLyonX (Twitter): x.com/drgabriellelyonApply to become a patient – https://drgabriellelyon.com/new-patient-inquiry/Join my weekly newsletter –

This week, we're in Missouri discussing tornado survivors who developed a rare infection. Then, we'll talk about the town that got away with murder. Buckle up and join us on this dark and twisted ride through the Show Me State.You may now join us on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠buy us a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cocktail⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Be sure to subscribe on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and leave a review, or, email us at unitedstatesofmurder@gmail.comFollow us on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sources: People, NIH, Science Daily, The GIST, The NY Times, Wikipedia - Ken Rex McElroy, ABC News, Skidmore, MissouriWatch: The Twister: Caught in the StormMusic by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Pixabay⁠⁠⁠⁠⁠⁠⁠